A Phase 3 interventional study of apatinib and placebo in Advanced or Metastatic Gastric Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-10-17.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing apatinib in Stomach Neoplasms — 14 open to participants now, 15 under way, 4 of them phase 3. apatinib · Stomach Neoplasms.
Among the 57 studies testing apatinib in Stomach Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2011, is one of 9 in phase 3, and was the 2nd registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →14 of the 57 studies testing apatinib in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Jingdong Zhang · Sites in China
Ages 18+
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Zuoyi Jiao · Sites in China
Ages 18–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 38 · Phase 3 13 · Phase 4 3
First in 2009; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 47 across the 57 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 57 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 5 open now, 5 under way, 2 of them phase 3. Of 6 finished, 2 (33%) have results posted.
Among the 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 4 in phase 3, and was the 1st registered.
Jiangsu HengRui Medicine Co., Ltd.’s Stomach Neoplasms studies by the year they started, since 2011.
2 of the studies testing apatinib in Stomach Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314203Phase 3Fujian Medical UniversityClinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer | 2027-08-25 |
| NCT03219593The First Affiliated Hospital of Bengbu Medical UniversityApatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 57 studies testing apatinib in Stomach Neoplasms, from their registry updates:
Among Jiangsu HengRui Medicine Co., Ltd.’s 14 in Stomach Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival or overall survival compared with placebo in patients with metastatic gastric carcinoma who failed two lines of chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: apatinib
Drug: placebo
apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Progression Free Survival(PFS)
Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Time frame: 30 months
Overall Survival(OS)
Overall Survival of the Participants
Time frame: 30 months
Disease Control Rate(DCR)
Disease control is defined as the proportion of patients who had a best response rating of complete response, partial response, or stable disease, and lasted at least 4 weeks.
Time frame: 30 months
Objective Response Rate(ORR)
Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR)
Time frame: 30 months
Percentage of Participants With Adverse Events
Time frame: 30 months
| Milestone | Apatinib | Placebo |
|---|---|---|
| Started | 176 | 91 |
| Completed | 136 | 71 |
| Not completed | 40 | 20 |
| Withdrew: Adverse event | 22 | 3 |
| Withdrew: Death | 9 | 13 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
| month | Apatinib | Placebo |
|---|---|---|
| Progression Free Survival(PFS) | 2.6 (2.0 to 2.9) | 1.8 (1.4 to 1.9) |
Overall Survival of the Participants
| month | Apatinib | Placebo |
|---|---|---|
| Overall Survival(OS) | 6.5 (4.8 to 7.6) | 4.7 (3.6 to 5.4) |
Disease control is defined as the proportion of patients who had a best response rating of complete response, partial response, or stable disease, and lasted at least 4 weeks.
| percentage of participants | Apatinib | Placebo |
|---|---|---|
| Disease Control Rate(DCR) | 42.05 | 8.79 |
Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR)
| percentage of participants | Apatinib | Placebo |
|---|---|---|
| Objective Response Rate(ORR) | 2.84 | 0.00 |
| percentage of participants | Apatinib | Placebo |
|---|---|---|
| Percentage of Participants With Adverse Events | 98.30 | 90.11 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apatinib | — | 6/176 (3.4%) | 173/176 (98.3%) |
| Placebo | — | 6/91 (6.6%) | 82/91 (90.1%) |
| Event | Apatinib | Placebo |
|---|---|---|
| Gastrointestinal bleedingGastrointestinal disorders | 5/176 | 5/91 |
| Abdominal painGastrointestinal disorders | 1/176 | 1/91 |
| Event | Apatinib | Placebo |
|---|---|---|
| proteinuriaRenal and urinary disorders | 84/176 | 15/91 |
| leukopeniaBlood and lymphatic system disorders | 71/176 | 8/91 |
| neutropeniaBlood and lymphatic system disorders | 66/176 | 9/91 |
| hypertensionVascular disorders | 62/176 | 5/91 |
| hand-foot syndromeSkin and subcutaneous tissue disorders | 49/176 | 2/91 |
| elevated transaminaseHepatobiliary disorders | 49/176 | 20/91 |
| anemiaBlood and lymphatic system disorders | 44/176 | 22/91 |
| thrombocytopeniaBlood and lymphatic system disorders | 44/176 | 6/91 |
| hyperbilirubinemiaHepatobiliary disorders | 43/176 | 13/91 |
| bleedingBlood and lymphatic system disorders | 35/176 | 22/91 |
5 participants in the apatinib group and 1 in the placebo group withdrew from the study before receiving the assigned treatments.As a result,267 randomly assigned participants were included in Full Analysis Set (FAS),with 176 assigned to the apatinib group and 91 assigned to the placeo group.
| Age, Continuous(years) | Apatinib | Placebo | Total |
|---|---|---|---|
| Mean | 55.01 ± 9.92 | 56.08 ± 9.74 | 55.37 ± 9.81 |
| Sex: Female, Male(Participants) | Apatinib | Placebo | Total |
|---|---|---|---|
| Female | 44 | 22 | 66 |
| Male | 132 | 69 | 201 |
The record gives a start of Jan 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apatinib
Jiangsu HengRui Medicine Co., Ltd. →